The Phase I study is assessing use of a GSK pandemic adjuvant in combination with COVID-19 vaccine candidate SCB-2019Original Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.